Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Kassner, U.
76  Ergebnisse:
Personensuche X
?
1

High interindividual variability in LDL-cholesterol reducti..:

Makhmudova, U. ; Schatz, U. ; Perakakis, N....
Clinical Research in Cardiology.  112 (2023)  11 - p. 1639-1649 , 2023
Link: https://doi.org/10.1007/..
 
?
2

High individual variability in LDL-reductions after inclisi..:

Makhmudova, U ; Schatz, U ; Kassner, U...
European Heart Journal.  43 (2022)  Supplement_2 - p. , 2022
Link: https://doi.org/10.1093/..
 
?
3

New data of the treatment with bempedoic acid in clinical r..:

Schumann, F. ; Steinhagen-Thiessen, E. ; Bobbert, T..
Atherosclerosis.  355 (2022)  - p. 224 , 2022
Link: https://doi.org/10.1016/..
 
?
4

Cerebrotendinous xanthomatosis – three patients, three face:

Schumann, F. ; Steinhagen-Thiessen, E. ; Kassner, U.
Atherosclerosis.  331 (2021)  - p. e182-e183 , 2021
Link: https://doi.org/10.1016/..
 
?
5

Long-term treatment effect of lipoprotein apheresis in pati..:

Schumann, F. ; Haberbosch, L. ; Rosada, A...
Atherosclerosis.  315 (2020)  - p. e145 , 2020
Link: https://doi.org/10.1016/..
 
?
6

Clinical differentiation and mutation spectrum of chylomicr..:

Bardey, F. ; Rieck, L. ; Spira, D....
Atherosclerosis.  315 (2020)  - p. e43 , 2020
Link: https://doi.org/10.1016/..
 
?
7

Short Report Of A Longterm Outcome Of A Patient With Lysoso..:

Kassner, U. ; Soll, D. ; Hollstein, T....
Atherosclerosis.  287 (2019)  - p. e202 , 2019
Link: https://doi.org/10.1016/..
 
?
8

Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies (P..:

Kassner, U. ; Hollstein, T. ; Schumann, F....
Atherosclerosis.  287 (2019)  - p. e212 , 2019
Link: https://doi.org/10.1016/..
 
?
9

Treatment With Proprotein Convertase Subtilisin/Kexin Type ..:

Schumann, F. ; Hollstein, T. ; Steinhagen-Thiessen, E..
Atherosclerosis.  287 (2019)  - p. e215-e216 , 2019
Link: https://doi.org/10.1016/..
 
?
10

5001PCSK9-Inhibitor treatment of cardiovascular high risk p..:

Kassner, U ; Hollstein, T ; Grenkowitz, T...
European Heart Journal.  39 (2018)  suppl_1 - p. , 2018
Link: https://doi.org/10.1093/..
 
?
11

PCSK9-Inhibitor treatment of cardiovascular high risk patie..:

Hollstein, T. ; Grenkowitz, T. ; Scharnagl, H....
Atherosclerosis.  275 (2018)  - p. e31 , 2018
Link: https://doi.org/10.1016/..
 
?
12

Schwere Hypertriglyzeridämie: Diagnostik und neue Therapiep..:

Kassner, U. ; Dippel, M. ; Steinhagen-Thiessen, E.
Der Internist.  58 (2017)  8 - p. 866-876 , 2017
Link: https://doi.org/10.1007/..
 
?
13

Effect of different lipid apheresis methods on plasma polyu..:

Schmöcker, C. ; Kassner, U. ; Ostermann, A.I....
Atherosclerosis Supplements.  30 (2017)  - p. 193-199 , 2017
Link: https://doi.org/10.1016/..
 
?
14

Treatment of therapy-refractory hypercholesterolemia with p..:

Hollstein, T. ; Spira, D. ; Buchmann, N....
Atherosclerosis.  252 (2016)  - p. e48 , 2016
Link: https://doi.org/10.1016/..
 
?
15

A lipidomic analysis approach in patients undergoing lipopr..:

Schmöcker, C. ; Kassner, U. ; Kiesler, S....
Atherosclerosis.  249 (2016)  - p. 30-35 , 2016
Link: https://doi.org/10.1016/..
 
1-15